Literature DB >> 22371359

Hypercontrols in genotype-phenotype analysis reveal ancestral haplotypes associated with essential hypertension.

Eros Balam-Ortiz1, Adolfo Esquivel-Villarreal, David Huerta-Hernandez, Juan Carlos Fernandez-Lopez, Luis Alfaro-Ruiz, Omar Muñoz-Monroy, Ruth Gutierrez, Enrique Figueroa-Genis, Karol Carrillo, Adela Elizalde, Alfredo Hidalgo, Mauricio Rodriguez, Maki Urushihara, Hiroyuki Kobori, Gerardo Jimenez-Sanchez.   

Abstract

The angiotensinogen gene locus has been associated with essential hypertension in most populations analyzed to date. Increased plasma angiotensinogen levels have been proposed as an underlying cause of essential hypertension in whites; however, differences in the genetic regulation of plasma angiotensinogen levels have also been reported for other populations. The aim of this study was to analyze the relationship between angiotensinogen gene polymorphisms and haplotypes with plasma angiotensinogen levels and the risk of essential hypertension in the Mexican population. We genotyped 9 angiotensinogen gene polymorphisms in 706 individuals. Four polymorphisms, A-6, C4072, C6309, and G12775, were associated with increased risk, and the strongest association was found for the C6309 allele (χ(2)=23.9; P=0.0000009), which resulted in an odds ratio of 3.0 (95% CI: 1.8-4.9; P=0.000006) in the recessive model. Two polymorphisms, A-20C (P=0.003) and C3389T (P=0.0001), were associated with increased plasma angiotensinogen levels but did not show association with essential hypertension. The haplotypes H1 (χ(2)=8.1; P=0.004) and H5 (χ(2)=5.1; P=0.02) were associated with essential hypertension. Using phylogenetic analysis, we found that haplotypes 1 and 5 are the human ancestral haplotypes. Our results suggest that the positive association between angiotensinogen gene polymorphisms and haplotypes with essential hypertension is not simply explained by an increase in plasma angiotensinogen concentration. Complex interactions between risk alleles suggest that these haplotypes act as "superalleles."

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371359      PMCID: PMC3306465          DOI: 10.1161/HYPERTENSIONAHA.111.176453

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  40 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

Review 2.  An evolutionary framework for common diseases: the ancestral-susceptibility model.

Authors:  Anna Di Rienzo; Richard R Hudson
Journal:  Trends Genet       Date:  2005-09-08       Impact factor: 11.639

3.  A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies.

Authors:  D A Tregouet; V Garelle
Journal:  Bioinformatics       Date:  2007-02-18       Impact factor: 6.937

4.  Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies.

Authors:  N Kato; T Sugiyama; H Morita; H Kurihara; Y Yamori; Y Yazaki
Journal:  J Hypertens       Date:  1999-06       Impact factor: 4.844

5.  Essential hypertension and 5' upstream core promoter region of human angiotensinogen gene.

Authors:  T Ishigami; S Umemura; K Tamura; K Hibi; N Nyui; M Kihara; M Yabana; Y Watanabe; Y Sumida; T Nagahara; H Ochiai; M Ishii
Journal:  Hypertension       Date:  1997-12       Impact factor: 10.190

6.  Haplotype association analysis of AGT variants with hypertension-related traits: the HyperGEN study.

Authors:  C Charles Gu; Yen-Pei C Chang; Steven C Hunt; Karen Schwander; Donna Arnett; Luc Djousse; Gerardo Heiss; Al Oberman; Jean-Marc Lalouel; Mike Province; Aravinda Chakravarti; D C Rao
Journal:  Hum Hered       Date:  2005-12-12       Impact factor: 0.444

7.  Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population.

Authors:  P M Frossard; S H Hill; Y I Elshahat; E N Obineche; A M Bokhari; G G Lestringant; A John; A M Abdulle
Journal:  Clin Genet       Date:  1998-10       Impact factor: 4.438

8.  Novel sandwich ELISA for human angiotensinogen.

Authors:  Akemi Katsurada; Yoshiaki Hagiwara; Kazuya Miyashita; Ryousuke Satou; Kayoko Miyata; Naro Ohashi; L Gabriel Navar; Hiroyuki Kobori
Journal:  Am J Physiol Renal Physiol       Date:  2007-06-06

9.  Genetic polymorphisms of angiotensinogen and essential hypertension in a Tibetan population.

Authors:  Wenquan Niu; Yue Qi; Weijun Cen; Chaoying Cui; Ciren Zhuoma; Dan Cai; Wenyu Zhou; Changchun Qiu
Journal:  Hypertens Res       Date:  2007-11       Impact factor: 3.872

Review 10.  Genetics and hypertension.

Authors:  Alan B Weder
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-03       Impact factor: 3.738

View more
  4 in total

Review 1.  Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.

Authors:  Hiroyuki Kobori; Maki Urushihara
Journal:  Pflugers Arch       Date:  2012-08-24       Impact factor: 3.657

2.  Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.

Authors:  Sungeun Kim; Shanker Swaminathan; Mark Inlow; Shannon L Risacher; Kwangsik Nho; Li Shen; Tatiana M Foroud; Ronald C Petersen; Paul S Aisen; Holly Soares; Jon B Toledo; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Brenna C McDonald; Martin R Farlow; Bernardino Ghetti; Andrew J Saykin
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

3.  A functional variant in ST2 gene is associated with risk of hypertension via interfering MiR-202-3p.

Authors:  Fangqin Wu; Lu Li; Qiang Wen; Jinhua Yang; Zhuyue Chen; Peng Wu; Meian He; Xiaomin Zhang; Tangchun Wu; Longxian Cheng
Journal:  J Cell Mol Med       Date:  2017-01-25       Impact factor: 5.310

4.  Prevalence and association of microalbuminuria in essential hypertensive patients.

Authors:  Bibek Poudel; Binod Kumar Yadav; Ashwini Kumar Nepal; Bharat Jha; Kanak Bahadur Raut
Journal:  N Am J Med Sci       Date:  2012-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.